Merrimack Pharmaceuticals, Inc. (MACK) earnings
Quarterly and annual MACK reports and results, each read against the price at its own news timestamp. Back to the MACK overview →
5 measured MACK earnings events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q MERRIMACK PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | -0.10% | -0.07% | |
| Form 10-K/A MERRIMACK PHARMACEUTICAL For: Dec 31 | SEC filing · Form 10-K | +0.03% | +0.20% | |
| Form 10-K MERRIMACK PHARMACEUTICAL For: Dec 31 | SEC filing · Form 10-K | +0.00% | -0.41% | |
| Form 10-Q MERRIMACK PHARMACEUTICAL For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +0.81% | |
| Merrimack Reports Third Quarter 2023 Financial Results | Press release | +0.00% | +0.81% |
Keep exploring
More MACK: analyst actions → · SEC filings → · MACK overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Nova Leap Health Corp (NLH_CDNX) | 42 | 0.00% | 20% |
| Regional Health Properties, Inc. (RHE) | 42 | +1.71% | 61% |
| PROTOKINETIX INC (PKTX) | 41 | 0.00% | 14% |
| Vascular Biogenics Ltd. - Ordinary Shares (VBLT) | 41 | -4.03% | 0% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.